Hualan Biological Engineering Inc.
002007
Rang in Aktien
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Aktienkurs
$1.92
Marktkapitalisierung
$3.50B
Veränderung (1 Tag)
-1.39%
Veränderung (1 Jahr)
-19.45%
Land
CN
Handel Hualan Biological Engineering Inc. (002007)
Kategorie
Healthcare
P/S-Verhältnis für Hualan Biological Engineering Inc. (002007)
P/S-Verhältnis zum October 2026 TTM: 5.36
Laut den neuesten Finanzberichten und dem Aktienkurs von Hualan Biological Engineering Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 5.36. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 7.02.
P/S-Verlauf für Hualan Biological Engineering Inc. von 2001 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 5.36 | -11.26% |
| 2025 | 6.04 | -14.05% |
| 2024 | 7.02 | -7.05% |
| 2023 | 7.56 | -17.31% |
| 2022 | 9.14 | -23.59% |
| 2021 | 11.96 | -21.76% |
| 2020 | 15.29 | 15.15% |
| 2019 | 13.28 | 53.61% |
| 2018 | 8.64 | -21.68% |
| 2017 | 11.04 | -35.77% |
| 2016 | 17.18 | -1.12% |
| 2015 | 17.38 | 11.70% |
| 2014 | 15.56 | 4.91% |
| 2013 | 14.83 | 19.00% |
| 2012 | 12.46 | -18.28% |
| 2011 | 15.25 | -31.02% |
| 2010 | 22.10 | 35.18% |
| 2009 | 16.35 | -8.44% |
| 2008 | 17.86 | -46.00% |
| 2007 | 33.07 | 232.46% |
| 2006 | 9.95 | 356.58% |
| 2005 | 2.18 | 14.63% |
| 2004 | 1.90 | -24.46% |
| 2003 | 2.52 | -31.73% |
| 2002 | 3.69 | -27.97% |
| 2001 | 5.12 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | 86.99% |
US
|
|
| 40.55 | 656.57% |
US
|
|
| 4.19 | -21.81% |
AU
|
|
| 10.44 | 94.84% |
NL
|
|
| 4.52 | -15.70% |
BE
|
